Cancer in Biological Technology
Navigation Links
Cancer in Biological Technology
Viral Genetics Creates Subsidiary to Develop Cancer Therapy
... in animal studies to not only directly cause cancer cells to die but also to synergize with existing ... disruption is a concept that has tantalized cancer researchers for decades. We believe that we ... the senior director for infectious disease and cancer at Hollis Eden Pharmaceuticals. He served as ...... novel antibody therapeutics that target cancer stem cells, today announced the publication in ... potent anti-cancer activity in colon and breast cancer models for the company's first product candidate, ... the therapeutic potential of targeting cancer stem cells to treat solid tumors. OMP-21M18 is ...
Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305
... on developing proprietary targeted medicines for cancer treatment and Debiopharm Group (Debiopharm), a ... we believe may offer future benefit to cancer patients," said Dan Passeri, Curis President and ... basal cell carcinoma, metastatic colorectal cancer and advanced ovarian cancer," said Michael Gray, ...The Breast Cancer Therapeutics Market in Australia
... /PRNewswire/ -- Rising public awareness of breast cancer and available treatments have increased revenues in the breast cancer therapeutics market in Australia. As the most common cancer diagnosed in Australia's female population, the ...TSH Testing Raises Awareness of Importance of Thyroid Health
... in the U.S. even though the rate of thyroid cancer has nearly tripled since 1980," said Joseph ... four counties neighboring Indian Point, thyroid cancer is 70% above the U.S. rate and newborn ... a damaged thyroid can be." "The National cancer Institute is looking at Iodine 131, the most ...ImmunoVaccine Technologies Partners With Scancell to Advance DNA Vaccine Delivery
... Plc (SCLP.PL), which is developing therapeutic cancer and infectious disease vaccines. This research ... and strategic partnering to develop therapeutic cancer and infection disease vaccines. In 2008, Pfizer ... novel therapeutic vaccines for the treatment of cancer and infectious diseases based on its ...... picoplatin data from our colorectal and prostate cancer programs. These data further enhance the value ... 3 SPEAR trial of picoplatin in small cell lung cancer in the fourth quarter of 2009 with the goal of ... of this year. Colorectal cancer (CRC) : Presented new progression-free survival ...
Genomic Health Announces Second Quarter 2009 Financial Results and Business Progress
... Product revenue from the Onco type DX(R) breast cancer test was $35.2 million in the second quarter of ... type DX access and coverage to a broader breast cancer population," said Kim Popovits, President and ... Onco type DX to more than 100,000 breast cancer patients and today remain on track to make our ...Oncothyreon appoints Diana Hausman as Vice President of Clinical Development
... "Her leadership and knowledge of all aspects of cancer drug development will be very important as we ... at an exciting target at the forefront of current cancer drug research." Dr. Hausman joins Oncothyreon ... potential to improve the lives and outcomes of cancer patients. For more information, visit ...... GVHD, a common disorder among immunocompromised cancer patients after receiving allogeneic stem cell or ... clinical trial conducted at the Fred Hutchinson cancer Research Center. The second trial was a ... to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, ...
W.M. Keck Foundation Awards $1 Million to Hutchinson Center Scholar to Study How Cells Go Awry
... /PRNewswire/ -- Anyone touched by the ravages of cancer knows the rapidly growing, opportunistic cells don't play fair. But in order to expose exactly how cancer cells cheat their host, scientists must first ... - which enhances the potential for learning how cancer cells cheat - Fred ...... a patient's T cells to seek out and destroy cancer cells. In June, Micromet announced that ... regimens, but retained a detectable level of ALL cancer cells in their bone marrow - so called minimal ... T cells of a patient's immune system to eliminate cancer cells. Five of Micromet's antibodies are ...
Oncothyreon announces presentation of long-term Stimuvax data at World Conference on Lung Cancer
... of Lung Cancer's 13th World Conference on Lung cancer in San Francisco on August 1, 2009. The presentation by Dr. Glenwood Goss from the Ottawa Hospital cancer Centre, Ottawa, Ontario, involved 16 patients who ... patients with stage IIIb/IV non-small cell lung cancer (NSCLC). As of the time of data analysis in ...... About Multiple Myeloma Multiple myeloma, a cancer of the plasma cell, is an incurable but treatable ... hematologic cancer, representing 1% of all cancer diagnoses and 2% of all cancer deaths. According to the ...
CuraGen Reports Second Quarter 2009 Financial Results
... the development opportunities for CR011 in breast cancer and melanoma," commented Dr. Timothy M. Shannon, ... forward to presenting updated data for the breast cancer study in the second half of 2009." In ... development opportunities for CR011 in breast cancer and melanoma and the expected timing for ...Stemline Therapeutics CEO to Present at IBC's New Frontiers in Cancer Drug Development Conference
... developer of oncology compounds directed to cancer stem cell targets, today announced that the ... been invited to present at the New Frontiers in cancer Drug Development conference which is part of ... entitled "Developing Drug Candidates Directed to cancer Stem Cell Targets: Preclinical and Clinical ...Oncolytics Biotech(R) Inc. Announces 2009 Second Quarter Results
... a patient with progressive breast cancer who experienced a PR (34% shrinkage in ... the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program ... belief as to the potential of REOLYSIN as a cancer therapeutic; the Company's expectations as to the ...Sunesis Reports Financial Results for the Second Quarter 2009
... in women with platinum-resistant ovarian cancer were also presented at the ASCO 2009 Annual ... Leukemia AML is a rapidly progressing cancer of the blood characterized by the uncontrolled ... for new treatment options. About Ovarian cancer In the United States, ...Sanofi-aventis Announces Second Quarter 2009 Results
... 584 million, driven by its use in adjuvant breast cancer treatment and in prostate cancer. Growth was good ... 34 million, boosted in particular by the prostate cancer indication approved in the second half of 2008. ... , the leading cytotoxic agent in the colorectal cancer market as an adjuvant and as a first-line ...Poniard Pharmaceuticals to Host Second Quarter 2009 Financial Results Conference Call on August 4
... profile relative to existing platinum-based cancer therapies. Picoplatin is designed to overcome ... in solid tumors, and is being studied in multiple cancer indications, combinations and formulations. ... include a Phase 3 trial in small cell lung cancer and Phase 2 trials in metastatic colorectal and ...NeoGenomics Reports Second Quarter 2009 Results
... capability to perform a portion of their bladder cancer FISH testing in-house while simultaneously ... As a result, revenue from this customer's bladder cancer FISH testing declined by $278,000 in Q2 09 ... to have the opportunity to develop certain other cancer tests over time, and to have Abbott as new 9.6% ...Oncolytics Biotech Inc. Successfully Completes 100-Litre cGMP Production of REOLYSIN(R)
... the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program ... belief as to the potential of REOLYSIN as a cancer therapeutic, involve known and unknown risks and ... projects, the efficacy of REOLYSIN as a cancer treatment, the success and timely completion of ...MuGard Data From UK Study Shows Prevention of Oral Mucositis in Head and Neck Cancer Patients
... a post approval study of MuGard in head and neck cancer patients undergoing radiation treatment in the UK ... undergoing radiation treatment for head and neck cancer experience some level of oral mucositis. This ... patients receiving radiotherapy for head and neck cancer and those undergoing stem cell transplantation ...... it will further increase its work in the areas of cancer supportive care, pulmonary fibrosis, and ... expert in the clinical treatment and research of cancer regimen-related mucosal toxicities, said the ... and biotechnology clients in the area of cancer supportive care is expected to grow sharply this ...
Peregrine Pharmaceuticals Licenses Anti-VEGF Antibodies to Affitech
... programs highlighted by our bavituximab Phase II cancer program, which is already generating promising ... in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product ...NewLink Genetics Corporation Closes $7.5 Million Financing
... the clinical development of its therapeutic cancer products. This financing involved additional ... one of the leaders in the expanding field of cancer immunotherapy," said Dr. Charles Link, Chairman ... our lead immunotherapy product for pancreatic cancer into pivotal clinical studies and to advance our ...Oncolytics Biotech(R) Inc. Completes Lyophilization Process for REOLYSIN(R)
... the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program ... belief as to the potential of REOLYSIN as a cancer therapeutic, involve known and unknown risks and ... projects, the efficacy of REOLYSIN as a cancer treatment, the success and timely completion of ...... "This technology should change the way in which cancer drugs are developed." For more ... these Tumorgrafts closely reflect human cancer biology and their response to drugs is predictive of clinical outcomes in cancer patients. Champions Biotechnology leverages its ...
... of Eisai Corporation of North America, and cancer Innovations, Inc. (CII), a privately held ... with potential applications in the treatment of cancer and neo-vascular disorders," said Toni Gray, ... therapeutic applications. About cancer Innovations, Inc. ...
... the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program ... belief as to the potential of REOLYSIN as a cancer therapeutic, involve known and unknown risks and ... projects, the efficacy of REOLYSIN as a cancer treatment, the success and timely completion of ...
... decision by the University of Florida Shands cancer Center (UFSCC) to select OnCore(r) products in ... of the contract, the UFSCC has become the 25th cancer center to adopt the OnCore platform. ... decision by the University of Florida Shands cancer Center (UFSCC) to select OnCore(r) products in ...
Santaris Pharma - Interim Report for the Period 1 January to 30 June 2009
... has now received all the remaining six novel cancer drug candidates from Santaris Pharma and Enzon ... associated with schizophrenia. Clin cancer Research In January 2009 Santaris Pharma ... suppressive microRNAs in lung cancer. cancer Research In January 2009 Santaris Pharma ...ImmunoVaccine Technologies Licenses Immunotope's Breast, Ovarian and Prostate Cancer Antigens
... into an agreement to exclusively license seven cancer antigens from Immunotope Inc., an antigen ... platform to develop DPX-0907, a therapeutic cancer vaccine. Within the next six months the company ... licensing agreement significantly advances our cancer immunotherapy capabilities and represents our ...Significant Milestone Marks the Beginning of FDA-Authorized Breast Cancer Trial
... focusing on the research and development of cancer immunotherapies, announces that the first patient in its breast cancer trial has begun to receive its dendritic cell ... of its immunotherapy on 27 Stage IV breast cancer patients who have failed conventional therapy. ...USC Hospitals Extend Relationship With Quantros to Manage Compliance and Risk
... University Hospital and USC Kenneth Norris, Jr. cancer Hospital at the University of Southern ... University Hospital and USC Kenneth Norris, Jr. cancer Hospital will continue to use the Quantros Safety ... teaching hospital closely aligned with USC Norris cancer Hospital and staffed by the faculty of USC's Keck ...First Catalog Cancer Biochip for Sequence Capture Now Available from febit
... announced today the launch of the first human cancer biochip for HybSelect, febit's highly automated ... Next-Generation Sequencing (NGS). The new catalog cancer biochip features 115 important genes which are reported to be associated with common types of cancer by the Wellcome Trust Sanger Institute. ...... and survival in patients with metastatic breast cancer (MBC), according to a newly published report in ... blood. "Measuring CTCs in metastatic breast cancer patients provides oncologists with an additional ... at The University of Texas M. D. Anderson cancer Center. "The CellSearch(R) CTC test provides an ...
... immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, was awarded a $50 ... of novel biologics for autoimmune disorders, cancer and infectious diseases. Since its founding in ... three proprietary technology platforms: (1) cancer stem-like cells; (2) Dual Affinity Re-Targeting ...
Johnson & Johnson Completes Acquisition of Cougar Biotechnology
... with metastatic, castration-resistant prostate cancer who have progressed after docetaxel-based ... with metastatic, castration-resistant prostate cancer who have yet to receive chemotherapy. One in six men will be diagnosed with prostate cancer in his lifetime, and the disease accounts for 10 ...... to serve as a positive resource to help so many cancer patients obtain lifesaving treatments," says ... the $10 million mark in November 2008. cancer imposes heavy economic burdens on patients and ... in need of financial assistance while undergoing cancer care simply because of the high cost of care." ...
Other ContentsexaminationexaminationexaminationexaminationexaminationexaminationexaminationexaminationphobiasphobiasactivityactivityactivityactivityactivityactivityactivityactivityactivityactivitypicaphysicianphysicianphysicianphysicianphysicianphysicianphysicianphysicianphysicianpimplepilespilespilesOther TagstrolltrolltrolltrollTomTomTomTomTomTomTomTomTom
(Date:12/2/2009)...cientist from the University of Salamanca and anot...nce of predators affects the behaviour of Acantho... Negev Desert in the Near East. According to the s...le and different prey if they are under pressure f...dicted this result, but until now there had been v...
(Date:12/2/2009)...c. 2, 2009) HOBOKEN, NJ According to the Nationa... Americans diagnosed with diabetes already have so...pathy, damage to the retina caused by leaky blood ...ith diabetes and is one of the most feared diabeti... patients who,ve had diabetes for 10 years or more...
(Date:12/1/2009)...rchers at the Yerkes National Primate Research Cen... the first transgenic prairie voles, an important ...bonding. The future application of this technolog...tic manipulations that will help identify the brai...ocial behaviors. This advancement may also have im...
Breaking Biology News(10 mins):Lizards change their diet to avoid predators 2Study shows pine bark improves circulation, swelling and visual acuity in early diabetic retinopathy 2Study shows pine bark improves circulation, swelling and visual acuity in early diabetic retinopathy 3Yerkes researchers create first transgenic prairie voles 2Pelosi Statement on House Committee Chairmens Draft Health Care Reform Proposal 49513 1Pelosi Statement on House Committee Chairmens Draft Health Care Reform Proposal 49513 2Mayo researchers 3A Dramatic outcomes in prostate cancer study 49509 1Mayo researchers 3A Dramatic outcomes in prostate cancer study 49509 2Children 26apos 3Bs National Medical Center Dedicates New Blood Donor Center 49506 1Children 26apos 3Bs National Medical Center Dedicates New Blood Donor Center 49506 2Children 26apos 3Bs National Medical Center Dedicates New Blood Donor Center 49506 3(Date:12/2/2009)...g youths are more likely to be advertised in magaz...nks consumed mainly by adults, resulting in dispro...alcohol ads, according to a new study. , Researc...lth, Johns Hopkins Bloomberg School of Public Heal...study -- published in this month,s issue of the ...
(Date:12/2/2009)...oes in the battle against drug abuse, but new rese...study dozens of human disease could claim that ro...be used as a simpler and more convenient animal mo...drugs of abuse on the brain. Their study appears o...y journal. , Andrew Ewing and colleagues note t...
(Date:12/2/2009)...h cholesterol and become obese? The same way as pe... , More importantly, according to two new studie...uit flies use the same molecular mechanisms as hum...l and a key form of stored fat that contributes to...y to learn more about the genetic and biological p...
(Date:12/2/2009)...nd ASML Receive Innovation Awards in October. , ...cember 2, 2009 -- ILS Technology, LLC, an industry...ity, today announced that the company and a promin...for technical innovation to the industry., , , , ...ety of Automation (ISA) named ILS Technology as th...
(Date:12/2/2009).../ -- Holly Potter, vice president, Public Relation...aiser Permanente, received the "PR Team Leader" aw...ational Press Club. ,, PR News, PR People A... professionals who day in and day out are making c...rs of this year,s program set the benchmark for PR...
Breaking Medicine News(10 mins):Health News:Alcohol companies target youths with magazine ads, new study shows 2Health News:Latest epidemic? High cholesterol, obesity in fruit flies 2Health News:Latest epidemic? High cholesterol, obesity in fruit flies 3Health News:ILS Technology and Customer ASML Recipients of Industry Recognition Awards 2Health News:Kaiser Permanente Public Relations Leader Wins PR People Award 2Health News:Kaiser Permanente Public Relations Leader Wins PR People Award 3[0] Alcohol companies target youths with magazine ads, new study shows[0] The buzz on fruit flies: New role in the search for addiction treatments[0] Latest epidemic? High cholesterol, obesity in fruit flies[0] ILS Technology and Customer ASML Recipients of Industry Recognition Awards[0] Kaiser Permanente Public Relations Leader Wins PR People Award
trollcosponsorsredefinefellowsSloanshunsinnovationsobservatoryneutrinoKoulopoulosTomarrivalhasnlawsuits
Other Tagsensure 2ensure 3ensure 4ensure 5ensure 6ensure 7ensure 8ensure 9ensure 10prevalent 2prevalent 3prevalent 4prevalent 5prevalent 6prevalent 7prevalent 8prevalent 9prevalent 10cocaine 2treating 2treating 3treating 4treating 5treating 6treating 7treating 8treating 9treating 10addressed 2addressed 3being 2being 3being 4being 5being 6being 7being 8being 9being 10countries 2countries 3countries 4countries 5countries 6countries 7countries 8countries 9countries 10
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |